Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Celldex Therapeutics - Stock

Celldex Therapeutics Stock

CLDX
US15117B2025
A2PEAB

Price

35.50
Today +/-
+0
Today %
+0 %
P

Celldex Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Celldex Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Celldex Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Celldex Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Celldex Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Celldex Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Celldex Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Celldex Therapeutics’s growth potential.

Celldex Therapeutics Revenue, EBIT and net profit per share

DateCelldex Therapeutics RevenueCelldex Therapeutics EBITCelldex Therapeutics Net Income
2029e870.14 M undefined0 undefined75.97 M undefined
2028e413.61 M undefined40.65 M undefined-123.03 M undefined
2027e60.2 M undefined-255.59 M undefined-246.06 M undefined
2026e2.3 M undefined-305.99 M undefined-243.5 M undefined
2025e2.83 M undefined-231.79 M undefined-198.1 M undefined
2024e2.77 M undefined-185.11 M undefined-155.63 M undefined
20236.88 M undefined-142.04 M undefined-141.43 M undefined
20222.36 M undefined-100.23 M undefined-112.33 M undefined
20214.65 M undefined-67.74 M undefined-70.51 M undefined
20207.42 M undefined-45.35 M undefined-59.78 M undefined
20193.57 M undefined-53.23 M undefined-50.88 M undefined
20189.54 M undefined-46.79 M undefined-151.18 M undefined
201712.74 M undefined-108.53 M undefined-93.03 M undefined
20166.79 M undefined-132.92 M undefined-128.53 M undefined
20155.48 M undefined-129.54 M undefined-127.2 M undefined
20143.59 M undefined-122.43 M undefined-118.08 M undefined
20134.11 M undefined-81.44 M undefined-81.55 M undefined
201211.2 M undefined-58.08 M undefined-59.12 M undefined
20119.27 M undefined-43.4 M undefined-44.8 M undefined
201046.79 M undefined-6.46 M undefined-2.53 M undefined
200915.18 M undefined-37.45 M undefined-36.53 M undefined
20087.46 M undefined-34 M undefined-47.5 M undefined
20071.41 M undefined-15.51 M undefined-15.07 M undefined
2006900,000 undefined-17.62 M undefined-17.83 M undefined
20053.09 M undefined-18.86 M undefined-18.1 M undefined
20046.86 M undefined-13.58 M undefined-13.2 M undefined

Celldex Therapeutics Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0002471010869631121036463017154691143561293742622260413870
----100.0075.0042.86--20.00-25.0050.00-33.33-50.00-66.67-100.00-50.00--100.00-33.3350.00-50.00--600.00114.29206.67-80.4322.22-63.64-25.0066.6720.00100.00-25.00-66.67133.33-42.86-50.00200.00-66.67--2,900.00588.33110.65
---100.00100.0085.7190.0080.0087.5083.3366.6766.6766.67-100.00100.00100.00-100.00100.00-100.00---42.8640.0073.91--25.00100.00---------------
000246987564201210360600036340013000000000000000
0-1-1-1-2-1-1-4-6-4-9-9-11-11-7-7-11-15-24-14-11-13-18-17-15-34-37-6-43-58-81-122-129-132-108-46-53-45-67-100-142-185-231-305-255400
----50.00-50.00-14.29-10.00-40.00-75.00-66.67-100.00-150.00-366.67-1,100.00-700.00-350.00-1,100.00--800.00-233.33-275.00-216.67-600.00--1,500.00-485.71-246.67-13.04-477.78-527.27-2,025.00-4,066.67-2,580.00-2,200.00-900.00-511.11-1,766.67-642.86-1,675.00-5,000.00-2,366.67-9,250.00-11,550.00-15,250.00-425.009.69-
0-1-10-1-1-1-3-4-3-7-11-8-10-13-51-11-21-22-13-12-13-18-17-15-47-36-2-44-59-81-118-127-128-93-151-50-59-70-112-141-155-198-243-246-12375
-------200.0033.33-25.00133.3357.14-27.2725.0030.00292.31-78.4390.914.76-40.91-7.698.3338.46-5.56-11.76213.33-23.40-94.442,100.0034.0937.2945.687.630.79-27.3462.37-66.8918.0018.6460.0025.899.9327.7422.731.23-50.00-160.98
0.010.020.020.040.050.050.050.060.070.070.080.090.10.120.140.180.240.290.320.340.350.410.410.550.550.951.322.122.633.855.325.966.476.778.5710.4414.5129.6442.8746.8948.45000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Celldex Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Celldex Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Celldex Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Celldex Therapeutics's financial health and stability.

Assets

Celldex Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Celldex Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Celldex Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Celldex Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19841985198619871988198919901991null19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-1-10-1-1-1-3-4-4-3-7-11-8-10-13-51-11-21-22-13-12-13-18-17-15-47-36-2-44-59-81-118-127-128-93-151-50-59-70-112-141
00000000000000001121111002354323445343323
00000000000000000000000000000000000000000
00000000001-1000-2070-4-11903430-37247610-6-12-15-40-1-313
0000000000020154409001003124564471326331295819162541
00000000000000000000000000001,0001,0001,0000000000000
00000000000000000000000000000000000000000
0-10-100-3-4-4-3-5-9-7-9-7-8-8-4-20-16-11-10-6-13-918-29-30-35-49-67-101-98-113-99-75-46-40-60-103-107
0000-10000-1-1-1-1000-10000-3-2-20-10-200-4-1-4-2-100-1-1-1-1
0000-102-60-3-1011501730031-1-2-201045-16-2-16-77-41-5068462917-98-21689-105
0000003-60-2-91270184003220001145-14-1-16-73-39-4571483017-96-21491-103
00000000000000000000000000000000000000000
00000000000000000000020200-210-7-3-110000000000
221100301414017061003941140923000100136832950193135129161702690216
22110030181801706100394114092502010-21028792891193145129161712724218
00000003300000000000000000000041000000242
00000000000000000000000000000000000000000
1011-2-110713-71240-62436-7-13013-8-11-93912-35-913144-14144-29-2-15-1332-4-95
-0.86-2.12-0.16-2.26-1.25-1.64-3.41-4.480-5.01-6.68-10.33-9.74-10.32-8.16-9.57-9.57-4.89-21.61-17.49-11.95-14-8.2-16.12-9.216.98-30.4-32.47-36.17-50.08-71.89-103.47-103.77-115.79-101.72-76.05-47.15-41.95-62.16-105.56-109.11
00000000000000000000000000000000000000000

Celldex Therapeutics stock margins

The Celldex Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Celldex Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Celldex Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Celldex Therapeutics's sales revenue. A higher gross margin percentage indicates that the Celldex Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Celldex Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Celldex Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Celldex Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Celldex Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Celldex Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Celldex Therapeutics Margin History

Celldex Therapeutics Gross marginCelldex Therapeutics Profit marginCelldex Therapeutics EBIT marginCelldex Therapeutics Profit margin
2029e100 %0 %8.73 %
2028e100 %9.83 %-29.74 %
2027e100 %-424.56 %-408.73 %
2026e100 %-13,332.94 %-10,610.05 %
2025e100 %-8,187.53 %-6,997.5 %
2024e100 %-6,673.16 %-5,610.43 %
2023100 %-2,063.66 %-2,054.76 %
2022100 %-4,247.03 %-4,759.75 %
2021100 %-1,456.77 %-1,516.34 %
2020100 %-611.19 %-805.66 %
2019100 %-1,491.04 %-1,425.21 %
2018100 %-490.46 %-1,584.7 %
2017100 %-851.88 %-730.22 %
2016100 %-1,957.58 %-1,892.93 %
2015100 %-2,363.87 %-2,321.17 %
2014100 %-3,410.31 %-3,289.14 %
201343.31 %-1,981.51 %-1,984.18 %
20123.84 %-518.57 %-527.86 %
20111.62 %-468.18 %-483.28 %
201074.2 %-13.81 %-5.41 %
200944.66 %-246.71 %-240.65 %
200850.27 %-455.76 %-636.73 %
2007100 %-1,100 %-1,068.79 %
2006100 %-1,957.78 %-1,981.11 %
2005100 %-610.36 %-585.76 %
2004100 %-197.96 %-192.42 %

Celldex Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Celldex Therapeutics earnings per share therefore indicates how much revenue Celldex Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Celldex Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Celldex Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Celldex Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Celldex Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Celldex Therapeutics Revenue, EBIT and net profit per share

DateCelldex Therapeutics Sales per ShareCelldex Therapeutics EBIT per shareCelldex Therapeutics Earnings per Share
2029e13.2 undefined0 undefined1.15 undefined
2028e6.28 undefined0 undefined-1.87 undefined
2027e0.91 undefined0 undefined-3.73 undefined
2026e0.03 undefined0 undefined-3.69 undefined
2025e0.04 undefined0 undefined-3.01 undefined
2024e0.04 undefined0 undefined-2.36 undefined
20230.14 undefined-2.93 undefined-2.92 undefined
20220.05 undefined-2.14 undefined-2.4 undefined
20210.11 undefined-1.58 undefined-1.64 undefined
20200.25 undefined-1.53 undefined-2.02 undefined
20190.25 undefined-3.67 undefined-3.51 undefined
20180.91 undefined-4.48 undefined-14.48 undefined
20171.49 undefined-12.66 undefined-10.86 undefined
20161 undefined-19.63 undefined-18.99 undefined
20150.85 undefined-20.02 undefined-19.66 undefined
20140.6 undefined-20.54 undefined-19.81 undefined
20130.77 undefined-15.31 undefined-15.33 undefined
20122.91 undefined-15.09 undefined-15.36 undefined
20113.52 undefined-16.5 undefined-17.03 undefined
201022.07 undefined-3.05 undefined-1.19 undefined
200911.5 undefined-28.37 undefined-27.67 undefined
20087.85 undefined-35.79 undefined-50 undefined
20072.56 undefined-28.2 undefined-27.4 undefined
20061.64 undefined-32.04 undefined-32.42 undefined
20057.54 undefined-46 undefined-44.15 undefined
200416.73 undefined-33.12 undefined-32.2 undefined

Celldex Therapeutics business model

Celldex Therapeutics is an American company specializing in the development and research of therapeutics for diseases of the immune system and cancer. The company was founded in 2004 and is headquartered in Hampton, New Jersey. Celldex Therapeutics was originally established as a subsidiary of Alteon Inc., which focused on developing drugs for heart diseases. In 2004, the company became independent. Celldex Therapeutics has continuously invested in the development of new medicines for various areas of oncology. Its business model is based on the development and marketing of innovative therapeutics. The company collaborates closely with leading research institutions in the field of immunology and oncology to develop new therapies. Celldex Therapeutics also has partnerships with major pharmaceutical companies such as Pfizer, Roche, and Bristol-Myers Squibb. The company is divided into different divisions, including the development of vaccines and immunotherapies for various types of cancer, as well as the development of protein therapeutics for the treatment of inflammatory diseases and other immune system disorders. Celldex Therapeutics has already launched several products or is currently developing them, including CDX-1127, a immunomodulatory antibody for cancer treatment; CDX-1135, a novel vaccine against the Epstein-Barr virus; CDX-1401, an immunotherapy for various types of cancer based on dendritic cells; and Glembatumumab vedotin, an antibody-drug conjugate for the treatment of different types of cancer. In summary, Celldex Therapeutics is a biotech company specialized in innovative therapies for cancer and immune system diseases. The company collaborates with research institutions and pharmaceutical companies to bring its products to patients. Its wide portfolio and expertise contribute to improving patient care. Celldex Therapeutics is one of the most popular companies on Eulerpool.com.

Celldex Therapeutics SWOT Analysis

Strengths

1. Innovative Drug Pipeline: Celldex Therapeutics Inc has a diverse and promising pipeline of innovative drug candidates, positioning the company for potential future success.

2. Strong Intellectual Property: The company holds a valuable portfolio of intellectual property rights, providing a competitive advantage and protection for their novel therapies.

3. Extensive Research and Development Capabilities: Celldex Therapeutics Inc invests significantly in research and development, fostering a culture of innovation and allowing for continuous advancement in their product offerings.

4. Established Partnerships: The company has formed strategic partnerships with renowned organizations, further supporting their research efforts and facilitating potential commercialization opportunities.

Weaknesses

1. Financial Dependence: Celldex Therapeutics Inc heavily relies on external funding sources, which may pose a risk to the company's financial stability if funding becomes limited or unavailable.

2. Limited Product Diversification: The current product portfolio of Celldex Therapeutics Inc mainly focuses on oncology treatments, making the company vulnerable to market fluctuations and risks associated with a single therapeutic area.

3. Clinical Trial Risks: The success of Celldex Therapeutics' drug candidates heavily depends on the outcomes of clinical trials. The failure or delay of these trials can significantly impact the company's financial performance.

Opportunities

1. Growing Demand for Innovative Therapies: The healthcare industry is witnessing an increasing demand for novel and effective therapies, presenting a significant market opportunity for Celldex Therapeutics Inc to commercialize their products.

2. Expansion into New Geographic Markets: The company has the potential to expand its market presence beyond its current geographic scope, tapping into new regions and accessing previously untapped patient populations.

3. Strategic Collaborations: Collaborating with other biopharmaceutical companies or research institutions can provide additional opportunities for Celldex Therapeutics Inc to leverage their expertise, accelerate research, and enhance market reach.

Threats

1. Intense Competition: The biopharmaceutical industry is highly competitive, with numerous established players and emerging startups. Celldex Therapeutics Inc faces the risk of competitors developing similar or superior therapies that could potentially erode their market share.

2. Regulatory Challenges: Stringent regulatory requirements governing drug development and approval processes can introduce delays and uncertainties for Celldex Therapeutics Inc's pipeline candidates, posing potential risks to their commercialization plans.

3. Pricing Pressure: The healthcare industry faces ongoing pricing pressure from payers and governmental authorities. Celldex Therapeutics Inc may encounter challenges in pricing their therapies competitively while sustaining profitability.

Celldex Therapeutics valuation based on historical P/E ratio, EBIT, and P/S ratio.

Celldex Therapeutics shares outstanding

The number of shares was Celldex Therapeutics in 2023 — This indicates how many shares 48.449 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Celldex Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Celldex Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Celldex Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Celldex Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Celldex Therapeutics Stock splits

In Celldex Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Celldex Therapeutics.

Celldex Therapeutics Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.71 -0.56  (20.89 %)2024 Q1
12/31/2023-0.76 -0.83  (-9.41 %)2023 Q4
9/30/2023-0.69 -0.81  (-17.04 %)2023 Q3
6/30/2023-0.68 -0.65  (4.41 %)2023 Q2
3/31/2023-0.64 -0.62  (3.82 %)2023 Q1
12/31/2022-0.6 -0.56  (6.95 %)2022 Q4
9/30/2022-0.59 -0.57  (3.09 %)2022 Q3
6/30/2022-0.52 -0.59  (-13.42 %)2022 Q2
3/31/2022-0.46 -0.49  (-5.81 %)2022 Q1
12/31/2021-0.43 -0.43  (-1.18 %)2021 Q4
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the Celldex Therapeutics stock

Eulerpool World ESG Rating (EESG©)

46/ 100

🌱 Environment

53

👫 Social

23

🏛️ Governance

61

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Celldex Therapeutics Stock Shareholders

%
Name
Stocks
Change
Date
9.83 % Wellington Management Company, LLP6,476,5611,044,72812/31/2023
9.21 % Fidelity Management & Research Company LLC6,073,162-200,88412/31/2023
5.51 % Eventide Asset Management, LLC3,630,0132,030,01312/31/2023
5.25 % RTW Investments L.P.3,463,201012/31/2023
5.03 % BlackRock Institutional Trust Company, N.A.3,313,502429,66812/31/2023
4.76 % Polar Capital LLP3,135,871709,11512/31/2023
4.61 % The Vanguard Group, Inc.3,035,675425,50012/31/2023
4.56 % Kynam Capital Management LP3,005,904-194,09612/31/2023
4.18 % Point72 Asset Management, L.P.2,756,122-866,01412/31/2023
3.67 % Bellevue Asset Management AG2,416,296516,29612/31/2023
1
2
3
4
5
...
10

Celldex Therapeutics Executives and Management Board

Mr. Anthony Marucci61
Celldex Therapeutics President, Chief Executive Officer, Director (since 2008)
Compensation 5.4 M
Dr. Tibor Keler64
Celldex Therapeutics Executive Vice President, Chief Scientific Officer
Compensation 2.29 M
Mr. Freddy Jimenez54
Celldex Therapeutics Senior Vice President, General Counsel
Compensation 2.17 M
Mr. Sam Martin52
Celldex Therapeutics Chief Financial Office, Senior Vice President, Secretary
Compensation 2.07 M
Dr. Diane Young67
Celldex Therapeutics Senior Vice President, Chief Medical Officer
Compensation 1.94 M
1
2
3
4

Celldex Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Gilead Sciences - Stock
Gilead Sciences
SupplierCustomer-0,45-0,27-0,690,170,510,19
Amgen - Stock
Amgen
SupplierCustomer-0,51-0,540,32-0,21-0,51-0,56
1

Celldex Therapeutics stock: Frequently Asked Questions

What values and corporate philosophy does Celldex Therapeutics represent?

Celldex Therapeutics Inc represents a commitment to advancing breakthrough immunotherapies to treat cancer and other devastating diseases. The company's corporate philosophy is rooted in scientific innovation, collaboration, and a patient-centric approach. Celldex Therapeutics Inc strives to develop novel therapies that harness the power of the immune system to target and eliminate cancer cells. With a focus on precision medicine, the company aims to personalize treatment options for patients through targeted therapies and combination approaches. Celldex Therapeutics Inc's dedication to scientific excellence and improving patient outcomes drives their mission to redefine the treatment landscape for cancer and other therapeutic areas.

In which countries and regions is Celldex Therapeutics primarily present?

Celldex Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Celldex Therapeutics achieved?

Celldex Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase 3 clinical trials for RINTEGA®, a targeted immunotherapy for glioblastoma patients, showing promising results. Celldex also made progress in advancing their novel bispecific antibody program, targeting solid tumors and hematologic malignancies. Furthermore, the company entered into strategic collaborations with renowned organizations, including Bristol-Myers Squibb. Celldex's achievements demonstrate their commitment to developing innovative therapies and partnerships that can potentially address critical unmet medical needs in cancer treatment.

What is the history and background of the company Celldex Therapeutics?

Celldex Therapeutics Inc is a renowned biotechnology company specializing in the development of innovative immunotherapies to treat various types of cancer. Established in 1983, Celldex Therapeutics has proven expertise in the field of antibody-based drugs and targeted cancer therapies. The company is dedicated to advancing scientific research and bringing novel treatments to patients in need. With a strong emphasis on clinical trials and strategic collaborations, Celldex Therapeutics has made significant contributions to the oncology community. As a leader in the biotech industry, Celldex Therapeutics Inc continually strives to improve patient outcomes and revolutionize cancer therapeutics.

Who are the main competitors of Celldex Therapeutics in the market?

The main competitors of Celldex Therapeutics Inc in the market include bigger biotechnology companies like Amgen, Inc., Gilead Sciences, Inc., and Novartis AG. These companies also focus on developing innovative therapies and medications for various diseases and medical conditions. Celldex Therapeutics Inc competes with these companies to secure a strong position in the biotechnology industry and gain market share.

In which industries is Celldex Therapeutics primarily active?

Celldex Therapeutics Inc is primarily active in the biopharmaceutical industry.

What is the business model of Celldex Therapeutics?

The business model of Celldex Therapeutics Inc focuses on the development and commercialization of targeted immunotherapies for the treatment of various forms of cancer. Celldex utilizes its expertise in antibody-based therapeutics and vaccines to design and develop innovative treatments that harness the body's immune system to fight cancer cells. The company's approach combines monoclonal antibodies, antibody-drug conjugates, immune modulators, and vaccines to deliver personalized therapies that can potentially improve patient outcomes. Celldex Therapeutics Inc aims to address unmet medical needs in oncology by advancing its pipeline of novel therapeutics and establishing strategic partnerships to drive the commercialization of its products.

What is the P/E ratio of Celldex Therapeutics 2024?

The Celldex Therapeutics P/E ratio is -11.05.

What is the P/S ratio of Celldex Therapeutics 2024?

The Celldex Therapeutics P/S ratio is 620.02.

What is the AlleAktien quality score of Celldex Therapeutics?

The AlleAktien quality score for Celldex Therapeutics is 5/10.

What is the revenue of Celldex Therapeutics 2024?

The expected Celldex Therapeutics revenue is 2.77 M USD.

How high is the profit of Celldex Therapeutics 2024?

The expected Celldex Therapeutics profit is -155.63 M USD.

What is the business model of Celldex Therapeutics

Celldex Therapeutics Inc is a biopharmaceutical company that focuses on the development of therapies for the treatment of cancer and other serious immunological diseases. The company has been listed on NASDAQ since 2004 and is headquartered in Hampton, New Jersey. The business model of Celldex Therapeutics is based on the development and commercialization of innovative therapies tailored to the needs of patients with specific types of cancer. The company specializes in the research and development of antibodies, immunotherapeutics, and other novel technologies that utilize the body's immune system to selectively attack and destroy cancer cells. The company is positioned in three business segments: 1. Cancer Therapeutics: Celldex develops immunotherapeutics that stimulate the body's immune system to selectively attack and destroy cancer cells. The key products in this segment are the monoclonal antibody glembatumumab vedotin and the bispecific molecule CDX-014, which is precisely targeted to biomarkers for detection. 2. Infectious Diseases: Celldex has developed a viral vaccine aimed at combating HPV infections that can cause cervical cancer. With the project-based CPM-Interest system, the company also seeks to combat diseases such as Covid19. 3. Solutions Services: Celldex also offers a wide range of solutions and services tailored to the needs of patients, physicians, hospitals, and the pharmaceutical industry. The solutions include targeted collaboration with business partners to obtain their support in drug development and bring their medications to market with high-quality clinical and preclinical data and low risk. Celldex Therapeutics is a company deeply rooted in research and development. The company continuously invests in innovative technologies and strategies to develop new and effective therapies for the treatment of cancer patients and other serious immunological diseases. In doing so, the company relies on close collaboration with partners from the pharmaceutical industry to optimize development pipelines. Overall, the business model of Celldex Therapeutics is characterized by close collaboration with various partners, continuous investment in research and development, and a clear focus on patient needs and cost-effective solutions. The company has established itself as an innovator in cancer research and constantly strives to develop new therapies and technologies to improve the lives of patients.

What is the Celldex Therapeutics dividend?

Celldex Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Celldex Therapeutics pay dividends?

The dividend cannot currently be calculated for Celldex Therapeutics or the company does not pay out a dividend.

What is the Celldex Therapeutics ISIN?

The ISIN of Celldex Therapeutics is US15117B2025.

What is the Celldex Therapeutics WKN?

The WKN of Celldex Therapeutics is A2PEAB.

What is the Celldex Therapeutics ticker?

The ticker of Celldex Therapeutics is CLDX.

How much dividend does Celldex Therapeutics pay?

Over the past 12 months, Celldex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celldex Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Celldex Therapeutics?

The current dividend yield of Celldex Therapeutics is .

When does Celldex Therapeutics pay dividends?

Celldex Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celldex Therapeutics?

Celldex Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Celldex Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celldex Therapeutics located?

Celldex Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celldex Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celldex Therapeutics from 7/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Celldex Therapeutics pay the last dividend?

The last dividend was paid out on 7/8/2024.

What was the dividend of Celldex Therapeutics in the year 2023?

In the year 2023, Celldex Therapeutics distributed 0 USD as dividends.

In which currency does Celldex Therapeutics pay out the dividend?

The dividends of Celldex Therapeutics are distributed in USD.

Other fundamentals and analyses of Celldex Therapeutics in the deep dive.

Our stock analysis for Celldex Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celldex Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.